Tenet indictment signals new era of healthcare fraud investigations

Posted On February 8, 2017 By OrthoSpineNews In Regulatory /

Written by Ayla Ellison – February 06, 2017

Dallas-based Tenet Healthcare agreed to pay approximately $514 million last October to resolve allegations the company paid kickbacks in exchange for patient referrals. Although Tenet settled the lawsuit, the federal government attached a name to the case last week when a former Tenet executive was charged for his alleged involvement in the scheme.

In an indictment filed Jan. 24, John Holland, who previously served as senior vice president of operations for Tenet’s Southern States Region and as CEO of North Fulton Medical Center in Roswell, Ga., is charged with one count of healthcare fraud and two counts of major fraud against the United States.

According to the Department of Justice, Mr. Holland and his co-conspirators circumvented Tenet’s internal accounting controls to pay illegal kickbacks and bribes to a clinic that referred undocumented pregnant patients to Tenet hospitals for Medicaid-covered deliveries. Federal prosecutors allege the illegal scheme helped Tenet bill the Georgia and South Carolina Medicaid programs for more than $400 million.

READ THE REST HERE

Vancouver biotech firm’s ‘3D bio-printing’ to create human tissue for transplant needs

Posted On February 8, 2017 By OrthoSpineNews In Biologics /

January 28, 2017 – from Chuck Chiang

Patients who tear, rupture or otherwise damage cartilage or other bodily tissue may one day be able to simply go to the hospital and get a replacement, if new “3D bioprinting” technology being developed by a Vancouver firm reaches its full potential.

Aspect Biosystems, which was spun off from UBC research efforts in 2013, says the technology can create — or “print out” — human tissue within minutes, and could one day be able to provide “on-demand parts” for ailing patients.

Tamer Mohamed, Aspect’s CEO, said tissue creation for medical use will need to go through a long process of regulatory testing and certification before seeing the light of day, which he expects will take years. But he added that, if all goes well, patients could see the technology in certain clinical environments “in less than 10 years”.

He noted that Aspect’s recent announcement of a research deal with pharmaceutical giant Johnson & Johnson to create 3D-printed meniscus tissue as an example of how the technology could one day be used.

READ THE REST HERE

Zimmer Biomet Announces the International Release of the Innovative Subchondroplasty® Procedure

Posted On February 8, 2017 By OrthoSpineNews In Extremities, Sports Medicine /

WARSAW, Ind., Feb. 7, 2017 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, announced today the international release of the Subchondroplasty^® (SCP^®) Procedure. The Company received CE Mark approval for the commercialization of its SCP Procedure to facilitate distribution in the European Union (EU) and other countries that recognize the CE Mark. Zimmer Biomet also received approval for distribution in Canada, Singapore, Malaysia and Hong Kong.

The SCP Procedure is a minimally invasive outpatient intervention that addresses the defects associated with subchondral bone marrow lesions (BMLs). Diagnosed using an MRI and physical exam, BMLs are associated with stress fractures or micro-fractures of the bone adjacent to the joint. Left untreated, these defects may lead to cartilage degeneration, limited function, pain and a greater risk for joint deterioration.

SCP is performed to repair chronic BMLs by filling them with AccuFill^® Bone Substitute Material, a porous injectable calcium phosphate (CaP). The bone substitute is then slowly resorbed and replaced with healthy bone, repairing the bone defect.

The procedure is usually performed along with arthroscopy for visualization and treatment of findings inside the joint. In some cases, an open or mini-open procedure is necessary for access to the defect.

“The Subchondroplasty procedure addresses a previously unmet need in my practice for patients with chronic and painful bone marrow lesions,” said Dr. Christopher Baker, orthopaedic surgeon at Florida Orthopedic Institute in Tampa, Fla. “These patients no longer benefit from conservative treatment, yet are not ready for total joint replacement surgery.”

Initially used only in bone defects of the knee, the SCP Procedure has been successfully performed in other areas including bones of the foot, ankle and hip. Zimmer Biomet now owns 36 patents and eight trademarks in this area, with numerous others still pending.

“The international release of the Subchondroplasty Procedure is a major milestone for our company and for patients with chronic bone marrow lesions,” said David Nolan, Zimmer Biomet Group President, Biologics, Extremities, Sports Medicine, Surgical, Trauma, Foot and Ankle, Office Based Technologies and Zimmer Biomet Signature Solutions. “The procedure offers a tool that fills a gap in the patient treatment algorithm for the surgeon. We are eager to begin our international commercial launch.”

For more information on the SCP Procedure, please visit www.subchondroplasty.com.

About Zimmer Biomet

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet’s expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see our periodic reports filed with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet’s filings with the SEC. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Accordingly, such forward-looking statements speak only as of the date made. Readers of this news release are cautioned not to place undue reliance on these forward-looking statements, since, while management believes the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/zimmer-biomet-announces-the-international-release-of-the-innovative-subchondroplasty-procedure-300403563.html

SOURCE Zimmer Biomet Holdings, Inc.

News Provided by Acquire Media

Acelity Announces Debt Reduction with Proceeds from Sale of LifeCell Business and Entry into New Credit Agreement

Posted On February 7, 2017 By OrthoSpineNews In Financial /

February 07, 2017

SAN ANTONIO–(BUSINESS WIRE)–Acelity L.P. Inc. (“Acelity”), a global advanced wound care company, today announced that, on February 3, 2017, its wholly-owned operating subsidiaries, Kinetic Concepts, Inc. and KCI USA, Inc. (collectively, the “Borrowers” or the “Issuers”) repaid in full their existing credit facilities and redeemed all outstanding principal amounts of their 9.625% Second Lien Senior Secured Notes due 2021 and their 12.5% Senior Notes due 2019.

Additionally, the Borrowers, together with certain of Acelity’s other subsidiaries, entered into a new credit agreement which provides for a $1,085 million dollar term facility, €239 million euro term facility and a $300 million revolving facility. The term loan facilities will mature on February 3, 2024, and the revolving facility will mature on February 3, 2022.

“The completion of the sale of LifeCell and subsequent repayment of debt bolsters our balance sheet and significantly reduces our interest expense,” said Joe Woody, Acelity President and Chief Executive Officer. “This further positions us to focus on our leading advanced wound therapeutics business and the many opportunities we have to drive growth.”

About Acelity

Acelity L.P. Inc. and its subsidiaries are a global advanced wound care company that leverages the strengths of Kinetic Concepts, Inc. and Systagenix Wound Management, Limited. Available in more than 80 countries, the innovative and complementary ACELITY™ product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs nearly 5,000 people around the world.

Forward-Looking Statements

Certain statements included in this press release may be considered “forward-looking statements”, which are based on information available to Acelity on the date of this release. Words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “seek,” “foreseeable,” the negative versions of these words and or similar terms and phrases are used to identify these forward looking statements. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties. Acelity cannot assure you that future developments affecting Acelity will be those that have been anticipated. Actual results may differ materially from these expectations due to changes in global, regional or local economic, business, competitive, market regulatory and other factors, many of which are beyond Acelity’s control, as well as other risks described from time to time under “Risk Factors” in Acelity’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q (available at www.sec.gov). Any forward-looking statement speaks only as of the date of this press release. Factors or events that could cause Acelity’s actual results to differ may emerge from time to time, and it is not possible to predict all of them. Acelity may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the forward-looking statements. Acelity’s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments or other strategic transactions Acelity may make. Acelity undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Contacts

Acelity L.P. Inc.
Corporate Communications
Cheston Turbyfill, +1 210-515-7757
cheston.turbyfill@acelity.com
or
Investor Relations
Caleb Moore, +1 210-255-6433
caleb.moore@acelity.com

SpineGuard Extends the Utility of Its Dynamic Surgical Guidance (DSG ™) Technology Platform by Receiving US Patent for “Bone Quality Measurement” Application

Posted On February 7, 2017 By OrthoSpineNews In Regulatory /

PARIS & SAN FRANCISCO–(BUSINESS WIRE)–

SpineGuard (FR0011464452 – ALSGD), an innovative company that develops and markets disposable medical devices to make spine surgery safer, announced today it has been granted a patent by the US Patent Office for the application of its Dynamic Surgical Guidance technology for a new application: bone quality measurement.

“Because of population aging, orthopedists and neurosurgeons are treating an increasing number of osteoporotic patients, and they are expressing the need to precisely measure the bone quality. A widely shared opinion amongst surgeons is that the existing standard of care – known as a DEXA scan – only brings an uncertain (unreliable) answer to this growing need. This grant from the US Patent Office follows previous patent grants in China and Japan. It confirms the potential of SpineGuard’s DSG™ technology for this very promising new application,” said Pierre Jérôme, CEO and Co-founder of SpineGuard.

“We believe that the DSG™ technology can allow surgeons facing these skeletal pathologies to evaluate the bone density of their patients intraoperatively in a much more precise anatomical area and in doing so, to fine-tune their surgical strategy. For spine surgeries, this will ease the choice of the implants, their size, their diameter, their location and if cement should be used or not,” concluded Stéphane Bette, Co-founder, CTO and US General Manager of SpineGuard.

Osteoporosis represents a serious and growing healthcare issue due to population aging. Most patients with a fragility fracture are neither evaluated, nor treated for osteoporosis. For patients being diagnosed with osteoporosis, several complications are associated with spine surgeries, and the quality of the purchase of the pedicle screws is directly linked with the bone mineral density.

Sources :

Bouxsein ML, Kaufman J, Tosi L, Cummings S, Lane J, Johnell O. Recommendations for optimal care of the fragility fracture patient to reduce the risk of future fracture. J Am Acad Orthop Surg. 2004 Nov-Dec;12(6):385-95.
Lehman RA Jr, Kang DG, Wagner SC. Management of osteoporosis in spine surgery. J Am Acad Orthop Surg. 2015 Apr.23 (4):253-63. doi: 10.5435/JAAOS-D-14-00042.

More information on the DSG™ technology, its new applications and surgeons’ testimonials here.

Latest news release: FDA clearance to market DSG module for making pedicle screws smart, January 16, 2017

Next financial press release: 2016 full year financial results, March 23, 2017

SpineGuard will attend the 2017 Musculoskeletal Conference organized by Canaccord Genuity on March 14, 2017, at the occasion of the AAOS annual congress (American Association of Orthopedic Surgeons) in San Diego USA. SpineGuard’s CEO presentation will be broadcasted live and a replay will be available.

About SpineGuard^®
Co-founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard’s mission is to make spine surgery safer by bringing real-time digital technology into the operating room. Its primary objective is to establish its proprietary DSG™ (Dynamic Surgical Guidance) technology as the global standard of surgical care, starting with safer screw placement in spine surgery and then in other surgeries. PediGuard®, the first device designed using DSG, was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer. It is the world’s first and only handheld device capable of alerting surgeons to potential pedicular or vertebral breaches. Over 50,000 surgical procedures have been performed worldwide with DSG enabled devices. Numerous studies published in peer-reviewed medical and scientific journals have demonstrated the multiple benefits that PediGuard delivers to patients, surgical staff and hospitals. SpineGuard is expanding the scope of its DSG platform through strategic partnerships with innovative medical device companies and the development of smart instruments and implants. SpineGuard has offices in San Francisco and Paris. For further information, visit www.spineguard.com.

For further information, visit www.spineguard.com.

Disclaimer

The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170206005999/en/

MiMedx Board of Directors Authorizes $10 Million Increase to the Company’s Share Repurchase Program

Posted On February 7, 2017 By OrthoSpineNews In Financial /

MARIETTA, Ga., Feb. 6, 2017 /PRNewswire/ — MiMedx Group, Inc. (MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today the decision of its Board of Directors to authorize an increase in the Company’s Share Repurchase Program.

This action by the MiMedx Board of Directors authorizes an increase of $10 million to the Company’s Share Repurchase Program. This action brings the total authorized to $76 million since the Share Repurchase Program commenced in May 2014. The Company reported that in light of the prevailing market conditions, the Company’s available resources and other factors, the MiMedx Board of Directors believes the stock repurchases are a favorable investment for the Company. The Board agreed to review this program again at its scheduled meeting on February 22^nd, and to consider a substantial additional commitment to this beneficial program.

Parker H. “Pete” Petit, Chairman and CEO, stated, “Since the Share Repurchase Program commenced, our program has acquired approximately $65 million of our shares, which has proven to be very anti-dilutive. When we acquire shares at these very low prices, our high growth profile in both revenues and now profits produces an extremely anti-dilutive result. It is my personal belief that the Company’s stock price is very undervalued at present. Many investment bankers have told us they have this same opinion. Therefore, I would expect we will continue to take advantage of these current low prices to enhance shareholder value as permitted.”

Petit continued, “MiMedx management is just as frustrated with the volatility of our shares as are our shareholders. We know there are ongoing issues associated with naked short selling in our stock. These naked short selling practices are illegal, and we are continuing to be diligent in bringing to light the perpetrators of these illegal activities.”

“We believe the ‘fake allegations and fake news’ should be discredited when the Company publishes the key findings of the Report from the Audit Committee and the 2016 audited financial results on February 22nd,” concluded Petit.

About MiMedx

MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other human birth tissues, such as amniotic fluid, umbilical cord and placental collagen, and human skin and bone. “Innovations in Regenerative Biomaterials” is the framework behind our mission to give physicians products and tissues to help the body heal itself. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of amniotic tissue, having supplied over 700,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

Safe Harbor Statement

This press release includes statements that look forward in time or that express management’s beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, that the Company’s stock repurchases are a favorable investment for the Company, the belief that the Company’s stock price is very undervalued at present, the Company’s expectations to continue the use of the share repurchase program to enhance shareholder value, the Company’s belief that there are ongoing issues associated with naked short selling in the Company’s stock, and the current rumors should dissipate considerably when the Company publishes the key findings of the Report from its Audit Committee and the Company’s 2016 audited financial results. These statements are based on current information and belief, and are not guarantees of future performance. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the stock repurchases may not be a favorable investment for the Company, the Board may not consider a substantial new commitment to the share repurchase program at its February 22, 2017 meeting, the Company’s stock price may not be undervalued, the Company’s continued use of the share repurchase program may not enhance shareholder value or the Company may not continue to use the share repurchase program, there may not be ongoing issues associated with naked short selling or the issues may not be impacting the Company as believed, the current rumors and news may not dissipate considerably when the Company publishes the key findings of the Report from its Audit Committee and the Company’s 2016 audited financial results, and the risk factors detailed from time to time in the Company’s periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2015, and its most recent Form 10Q filing. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company’s disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.

Stryker at GMU to train Middle East surgeons on hip replacements

Posted On February 7, 2017 By OrthoSpineNews In Recon /

UAE, Feb 6: US-based Stryker, a global orthopedic implants and medical equipment provider, visited Gulf Medical University (GMU) on February 4 to organize a workshop on advanced hip replacement surgery titled, ‘Hip Replacement: Primary and Revision Course’. More than 12 leading Middle Eastern surgeons participated in the workshop organized by leading international orthopedic surgeons, professor Michael Nogler from the Medical University of Innsbruck (Austria) and professor Mohammad Ghazavi from the Scarborough Hospital (Toronto, Canada).

Speaking about the workshop, professor Hossam Hamdy, chancellor, GMU, said, “We are delighted to work with Stryker to host this unique platform that provides an opportunity to fine-tune the knowledge and skills of medical professionals in the UAE and GCC countries. Gulf Medical University’s Surgical Training Center is equipped with the latest technology and has ten surgical platforms providing advanced surgical training in all the surgical specialties. Today’s training course is one of the top programmes offered and supervised by leading international orthopedic surgeons from Canada and Austria.”

The extensive workshop began with an exclusive demonstration on fresh frozen cadavers, with two professors showcasing innovative new surgery techniques that allow patients to experience lesser pain, quicker recovery and improved mobility. Meanwhile, the participating surgeons from the Middle Eastern hospitals were given an opportunity to interact with the surgical team and seek answers to their queries, as the surgeries progressed.

On selecting GMU as the venue to host the programme, VioletaVelef, marketing manager Middle East of Stryker said: “Our choice of GMU for this training programme is largely due to the high-end cadaver lab facility here, which is quite rare in the region. Many universities do not have cadavers for the students. We firmly believe that trainings provided in cadaver labs are the best way to teach surgical techniques. I want to thank Gulf Medical University for hosting us here. We have done several activities in association with GMU, in the past two years and all our guests have given excellent feedback on the facilities here. This is one of the reasons we always look forward to collaborating with the university.”

Breakthrough Medical Imaging Solution Micro C™ Banks Additional $700k Seed Funding

Posted On February 7, 2017 By OrthoSpineNews In Extremities /

SAVANNAH, GEORGIA, UNITED STATES, February 3, 2017 /EINPresswire.com/ — As Micro C™ targets the high growth market of surgeries of the extremities, Greg Kolovich MD/MPH and Chief Medical Officer, Evan Ruff, CEO, and Kirby Sisk, COO are leveraging the additional funding to complete Q2 2017 Micro C™ milestones: prototype build, beta testing, FDA submission, and go-to-market launch activities including demonstrations at leading professional academies for orthopedic surgeons.

“At our sessions with orthopedic surgeons and ambulatory surgery center management, the feedback is consistent: They want to use the Micro C as soon as commercially available,” remarks Dr. Kolovich. “They are impressed with how we have incorporated multiple innovations into a compact digital X-ray and multi-modal camera that also integrates real-time, HIPPA compliant data and image transmission together with accurate billing and much greater accuracy, clarity, safety, and speed.”

Georgia-based technology boosters, including the Technology Association of Georgia and Georgia Tech’s Advanced Technology Development Center (ATDC) have recognized Micro C’s prowess with TAG’s Most Innovative Company award and ATDC’s Geekend Pitch Contest first place award.

“With seven patents filed, we believe that the intellectual property we created is not only winning us recognition, but will also contribute to building the value of our product and our company significantly,” explained CEO Evan Ruff. With responsibility for the production of the Micro C emitter, table and accessories, COO Kirby Sisk added, “Combining a compact and complex device with software, consumables, and service support will demand skills and resources that we are rapidly bringing on board with our investors’ confidence and backing.”

About Micro C™

Micro C™ is a groundbreaking medical imaging solution designed for surgeons and physicians treating disorders of the extremities that combines a compact, hand-held X-ray and digital still, video and infrared cameras, software, service and consumables. It is designed to deliver greater accuracy, clarity, safety, and speed, replacing 60-year-old x-ray and fluoroscopy equipment that is bulky, expensive and less safe. Invented by Greg Kolovich MD/MPH, experienced orthopedic surgeon and Chief Medical Officer and Founder, he leads the founding team of fellow Georgia Institute of Technology graduates with Evan Ruff as CEO and Kirby Sisk as COO.

Learn more about Micro C Imaging online including Facebook and Twitter.

Media Contact
Murem Sharpe
912.247.4255
murem.sharpe@microcimaging.com

Murem Sharpe
Micro C Imaging
912-247-4255
email us here

ChoiceSpine announces the launch of HARRIER™ ALIF

Posted On February 6, 2017 By OrthoSpineNews In Spine /

Knoxville, TN- February 6, 2017- ChoiceSpine, a Knoxville, TN based spinal implant company, announced the launch of HARRIER™, an anterior lumbar interbody fusion system. ChoiceSpine received 510K clearance the HARRIER™ in November 2016 and it will be the 1^st of 4 new products launching in 2017.

“Harrier fills a long needed gap in our product portfolio” says Anderson Collins, ChoiceSpine’s Director of Business Development. “We have had strong growth over the past 4 years, which has been a function of two key drivers, bringing new products to market and working the right distributor partners. Adding HARRIER™ to our portfolio gives us another revenue source that our distributor and surgeon partners can utilize to improve patients’ lives.”

ChoiceSpine’s Vice President of R&D Steve Ainsworth adds, “Our product pipeline is full of products we plan to launch over the next 2 years. HARRIER™ and other new products will help sustain the growth we have experienced over the past few years. Our R&D team has worked diligently with our distributor and surgeon partners to roll out HARRIER™ and we are confident it will be received well in the market.

NuVasive To Present At Leerink Partners 6th Annual Global Healthcare Conference 2017

Posted On February 6, 2017 By OrthoSpineNews In Spine /

SAN DIEGO, Feb. 6, 2017 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced that management will present at the Leerink Partners 6^th Annual Healthcare Conference at the Lotte New York Palace Hotel in New York, New York on Wednesday, February 15, 2017 at 11:00 a.m. ET / 8:00 a.m. PT.

A live webcast of the presentation will be available online from the Investor Relations page of the Company’s website at www.nuvasive.com. A replay of the presentation will remain available on the website for 30 days after the applicable live webcast.

About NuVasive NuVasive, Inc. (NASDAQ: NUVA) is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes. NuVasive’s highly differentiated, procedurally-integrated solutions include access instruments, implantable hardware and software systems for surgical planning and reconciliation technology that centers on achieving the global alignment of the spine. With $811 million in revenues (2015), NuVasive has an approximate 2,300 person workforce in more than 40 countries around the world. For more information, please visit www.nuvasive.com.

Forward-Looking Statements NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA™ platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

SOURCE NuVasive, Inc.

Our Blog

Contacts